Literature DB >> 30979411

Serum Metabolomics and Incidence of Atrial Fibrillation (from the Atherosclerosis Risk in Communities Study).

Alvaro Alonso1, Bing Yu2, Yan V Sun3, Lin Y Chen4, Laura R Loehr5, Wesley T O'Neal6, Elsayed Z Soliman7, Eric Boerwinkle8.   

Abstract

We have previously identified associations of 2 circulating secondary bile acids (glycocholenate and glycolithocolate sulfate) with atrial fibrillation (AF) risk in 1,919 blacks in the Atherosclerosis Risk in Communities cohort. We aimed to replicate these findings in an independent sample of 2,003 white and black Atherosclerosis Risk in Communities participants, and performed a new metabolomic analysis in the combined sample of 3,922 participants, followed between 1987 and 2013. Metabolomic profiling was done in baseline serum samples using gas and liquid chromatography mass spectrometry. AF was ascertained from electrocardiograms, hospitalizations, and death certificates. We used multivariable Cox regression to estimate hazard ratios (HR) and 95% confidence intervals (95%CI) of AF by 1 standard deviation difference of metabolite levels. Over a mean follow-up of 20 years, 608 participants developed AF. Glycocholenate sulfate was associated with AF in the replication and combined samples (HR 1.10, 95% CI 1.00, 1.21 and HR 1.13, 95% CI 1.04, 1.22, respectively). Glycolithocolate sulfate was not related to AF risk in the replication sample (HR 1.02, 95% CI 0.92, 1.13). An analysis of 245 metabolites in the combined cohort identified 3 additional metabolites associated with AF after multiple-comparison correction: pseudouridine (HR 1.18, 95% CI 1.10, 1.28), uridine (HR 0.86, 95% CI 0.79, 0.93) and acisoga (HR 1.17, 95% CI 1.09, 1.26). In conclusion, we replicated a prospective association among a previously identified secondary bile acid, glycocholenate sulfate, and AF incidence, and identified new metabolites involved in nucleoside and polyamine metabolism as markers of AF risk.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30979411      PMCID: PMC6529276          DOI: 10.1016/j.amjcard.2019.03.017

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  28 in total

1.  Global metabolomic profiling targeting childhood obesity in the Hispanic population.

Authors:  Nancy F Butte; Yan Liu; Issa F Zakeri; Robert P Mohney; Nitesh Mehta; V Saroja Voruganti; Harald Göring; Shelley A Cole; Anthony G Comuzzie
Journal:  Am J Clin Nutr       Date:  2015-06-17       Impact factor: 7.045

2.  A Metabolome-Wide Association Study of Kidney Function and Disease in the General Population.

Authors:  Peggy Sekula; Oemer-Necmi Goek; Lydia Quaye; Clara Barrios; Andrew S Levey; Werner Römisch-Margl; Cristina Menni; Idil Yet; Christian Gieger; Lesley A Inker; Jerzy Adamski; Wolfram Gronwald; Thomas Illig; Katja Dettmer; Jan Krumsiek; Peter J Oefner; Ana M Valdes; Christa Meisinger; Josef Coresh; Tim D Spector; Robert P Mohney; Karsten Suhre; Gabi Kastenmüller; Anna Köttgen
Journal:  J Am Soc Nephrol       Date:  2015-10-08       Impact factor: 10.121

3.  Associations between metabolomic compounds and incident heart failure among African Americans: the ARIC Study.

Authors:  Yan Zheng; Bing Yu; Danny Alexander; Teri A Manolio; David Aguilar; Josef Coresh; Gerardo Heiss; Eric Boerwinkle; Jennifer A Nettleton
Journal:  Am J Epidemiol       Date:  2013-06-20       Impact factor: 4.897

4.  Whole genome sequence analysis of serum amino acid levels.

Authors:  Bing Yu; Paul S de Vries; Ginger A Metcalf; Zhe Wang; Elena V Feofanova; Xiaoming Liu; Donna Marie Muzny; Lynne E Wagenknecht; Richard A Gibbs; Alanna C Morrison; Eric Boerwinkle
Journal:  Genome Biol       Date:  2016-11-24       Impact factor: 13.583

5.  Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension.

Authors:  Christopher J Rhodes; Pavandeep Ghataorhe; John Wharton; Kevin C Rue-Albrecht; Charaka Hadinnapola; Geoffrey Watson; Marta Bleda; Matthias Haimel; Gerry Coghlan; Paul A Corris; Luke S Howard; David G Kiely; Andrew J Peacock; Joanna Pepke-Zaba; Mark R Toshner; S John Wort; J Simon R Gibbs; Allan Lawrie; Stefan Gräf; Nicholas W Morrell; Martin R Wilkins
Journal:  Circulation       Date:  2016-11-21       Impact factor: 29.690

6.  An adipo-biliary-uridine axis that regulates energy homeostasis.

Authors:  Yingfeng Deng; Zhao V Wang; Ruth Gordillo; Yu An; Chen Zhang; Qiren Liang; Jun Yoshino; Kelly M Cautivo; Jef De Brabander; Joel K Elmquist; Jay D Horton; Joseph A Hill; Samuel Klein; Philipp E Scherer
Journal:  Science       Date:  2017-03-16       Impact factor: 47.728

7.  Metabolomic Profiling in Relation to New-Onset Atrial Fibrillation (from the Framingham Heart Study).

Authors:  Darae Ko; Eric M Riles; Ernaldo G Marcos; Jared W Magnani; Steven A Lubitz; Honghuang Lin; Michelle T Long; Renate B Schnabel; David D McManus; Patrick T Ellinor; S Vasan Ramachandran; Thomas J Wang; Robert E Gerszten; Emelia J Benjamin; Xiaoyan Yin; Michiel Rienstra
Journal:  Am J Cardiol       Date:  2016-08-24       Impact factor: 2.778

8.  Bile acids induce arrhythmias in human atrial myocardium--implications for altered serum bile acid composition in patients with atrial fibrillation.

Authors:  Peter P Rainer; Uwe Primessnig; Sandra Harenkamp; Bernhard Doleschal; Markus Wallner; Guenter Fauler; Tatjana Stojakovic; Rolf Wachter; Ameli Yates; Klaus Groschner; Michael Trauner; Burkert M Pieske; Dirk von Lewinski
Journal:  Heart       Date:  2013-07-26       Impact factor: 7.365

9.  Metabolomics and Incidence of Atrial Fibrillation in African Americans: The Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Alvaro Alonso; Bing Yu; Waqas T Qureshi; Morgan E Grams; Elizabeth Selvin; Elsayed Z Soliman; Laura R Loehr; Lin Y Chen; Sunil K Agarwal; Danny Alexander; Eric Boerwinkle
Journal:  PLoS One       Date:  2015-11-06       Impact factor: 3.240

Review 10.  Bile acid receptors as targets for drug development.

Authors:  Frank G Schaap; Michael Trauner; Peter L M Jansen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-08-27       Impact factor: 46.802

View more
  13 in total

1.  Serum metabolic signatures of subclinical atherosclerosis in patients with type 2 diabetes mellitus: a preliminary study.

Authors:  Jiaorong Su; Qing Zhao; Aihua Zhao; Wei Jia; Wei Zhu; Jingyi Lu; Xiaojing Ma
Journal:  Acta Diabetol       Date:  2021-04-19       Impact factor: 4.280

2.  Arginine catabolism metabolites and atrial fibrillation or heart failure risk: 2 case-control studies within the Prevención con Dieta Mediterránea (PREDIMED) trial.

Authors:  Leticia Goni; Cristina Razquin; Estefanía Toledo; Marta Guasch-Ferré; Clary B Clish; Nancy Babio; Clemens Wittenbecher; Alessandro Atzeni; Jun Li; Liming Liang; Courtney Dennis; Ángel Alonso-Gómez; Montserrat Fitó; Dolores Corella; Enrique Gómez-Gracia; Ramón Estruch; Miquel Fiol; Jose Lapetra; Lluis Serra-Majem; Emilio Ros; Fernando Arós; Jordi Salas-Salvadó; Frank B Hu; Miguel A Martínez-González; Miguel Ruiz-Canela
Journal:  Am J Clin Nutr       Date:  2022-09-02       Impact factor: 8.472

Review 3.  Gut Microbiota-Derived Metabolites and Cardiovascular Disease Risk: A Systematic Review of Prospective Cohort Studies.

Authors:  Raul Sanchez-Gimenez; Wahiba Ahmed-Khodja; Yesica Molina; Oscar M Peiró; Gil Bonet; Anna Carrasquer; George A Fragkiadakis; Mònica Bulló; Alfredo Bardaji; Christopher Papandreou
Journal:  Nutrients       Date:  2022-06-27       Impact factor: 6.706

Review 4.  Gut microbiome and cardiometabolic risk.

Authors:  Ben Arpad Kappel; Massimo Federici
Journal:  Rev Endocr Metab Disord       Date:  2019-12       Impact factor: 6.514

5.  Multicohort Metabolomics Analysis Discloses 9-Decenoylcarnitine to Be Associated With Incident Atrial Fibrillation.

Authors:  Lars Lind; Samira Salihovic; Johan Sundström; Corey D Broeckling; Patrik K Magnusson; Jessica Prenni; Tove Fall; Johan Ärnlöv
Journal:  J Am Heart Assoc       Date:  2021-01-05       Impact factor: 5.501

6.  Altered Acylcarnitine Metabolism Is Associated With an Increased Risk of Atrial Fibrillation.

Authors:  Einar Smith; Celine Fernandez; Olle Melander; Filip Ottosson
Journal:  J Am Heart Assoc       Date:  2020-10-20       Impact factor: 5.501

7.  Non-targeted metabolomics identify polyamine metabolite acisoga as novel biomarker for reduced left ventricular function.

Authors:  Andreas Puetz; Anna Artati; Jerzy Adamski; Katharina Schuett; Francesco Romeo; Robert Stoehr; Nikolaus Marx; Massimo Federici; Michael Lehrke; Ben A Kappel
Journal:  ESC Heart Fail       Date:  2021-11-22

8.  Development of Alcohol-Associated Hepatitis Is Associated With Specific Changes in Gut-Modified Bile Acids.

Authors:  Mark D Muthiah; Ekaterina Smirnova; Puneet Puri; Naga Chalasani; Vijay H Shah; Calvin Kiani; Stephanie Taylor; Faridoddin Mirshahi; Arun J Sanyal
Journal:  Hepatol Commun       Date:  2022-01-04

9.  Glycolysis Metabolites and Risk of Atrial Fibrillation and Heart Failure in the PREDIMED Trial.

Authors:  Nerea Becerra-Tomás; Miguel Ruiz-Canela; Pablo Hernández-Alonso; Mònica Bulló; Jun Li; Marta Guasch-Ferré; Estefanía Toledo; Clary B Clish; Ramon Estruch; Emilio Ros; Montserrat Fitó; Chih-Hao Lee; Kerry Pierce; Fernando Arós; Lluís Serra-Majem; Liming Liang; Cristina Razquin; Enrique Gómez-Gracia; Miguel A Martínez-González; Frank B Hu; Dolores Corella; Jordi Salas-Salvadó
Journal:  Metabolites       Date:  2021-05-11

10.  Metabolic Signature of Arrhythmogenic Cardiomyopathy.

Authors:  Chiara Volani; Johannes Rainer; Vinicius Veri Hernandes; Viviana Meraviglia; Peter Paul Pramstaller; Sigurður Vidir Smárason; Giulio Pompilio; Michela Casella; Elena Sommariva; Giuseppe Paglia; Alessandra Rossini
Journal:  Metabolites       Date:  2021-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.